This trial will test how well neratinib works in treating breast cancer that has spread to the brain. Neratinib is a drug that may stop breast cancer cells from growing by inhibiting proteins that include HER2. The trial will look at how well neratinib works to decrease the size of or stabilize breast cancer in the brain, and also how it affects thinking and how much neratinib reaches the central nervous system.
1 Primary · 7 Secondary · Reporting Duration: 2 years
140 Total Participants · 4 Treatment Groups
Primary Treatment: Cohort 3a/3b · No Placebo Group · Phase 2
Age 18+ · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: